A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Study Summary

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.

Conditions

Cardiovascular Metabolic Disease Dyslipidemias Lipid Disorder Hypertriglyceridemia Heterozygous Familial Hypercholesterolemia (HeFH)Homozygous Familial Hypercholesterolemia (HoFH)Severe Hypertriglyceridemia (sHTG)Mixed Hyperlipemia Hypercholesterolaemia

Interventions / Drugs

CTX310

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment90 participants

Primary Completion—

Lead SponsorCRISPR Therapeutics AG

Data Retrieved2026-04-11 04:10:52.768013+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.